CervoMed
CRVO
8 hedge funds and large institutions have $513K invested in CervoMed in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
5,600% more capital invested
Capital invested by funds: $9K → $513K (+$504K)
300% more funds holding
Funds holding: 2 → 8 (+6)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$258K |
| 2 |
Goldman Sachs
New York
|
+$60.1K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$60.1K |
| 4 |
Morgan Stanley
New York
|
+$47.2K |
| 5 |
WTC
WhitTier Trust Company
Reno,
Nevada
|
+$38.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
CRVO Hedge Fund Activity: Q1 2017 in Review
8 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in CervoMed (CRVO) for Q1 2017, worth a combined $513K — up 5,600% from $9K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CRVO positions and 0 closed out — a net gain of 6 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $258K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1K.
- 8 institutional investors held CervoMed (CRVO) as of Q1 2017, up from 2 in Q4 2016.
- Funds reported $513K of CervoMed stock for Q1 2017, up 5,600% quarter-over-quarter.
- 6 funds opened new CervoMed positions in Q1 2017 and 0 closed out, a net change of +6 holders.
- The largest CervoMed buyer in Q1 2017 was Vanguard Group, an estimated $258K added.
- The largest CervoMed seller in Q1 2017 was Tower Research Capital (TRC), an estimated $1K sold.
Based on aggregated 13F filings for Q1 2017.